FDA shuns Outlook Therapeutics with wet AMD drug BLA rejection
Shares in the company tanked 80% following the FDA issued a CRL for its bevacizumab formulation.
Shares in the company tanked 80% following the FDA issued a CRL for its bevacizumab formulation.
What's Your Reaction?
